Sarepta Therapeutics Announces Publication of Positive Long-Term Safety and Efficacy Data for Eteplirsen in the Annals of Neurology

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. NVDA
2. ACN
3. SPCX
4. MSTR
5. MU
6. KR
7. ABBV
8. DFTX
9. BAUFF
10. RGNX

Go back to Sarepta Therapeutics Announces Publication of Positive Long-Term Safety and Efficacy Data for Eteplirsen in the Annals of Neurology

Buy Sarepta (SRPT) Into Kyndrisa Briefing Documents and Panel Outcome - Oppenheimer

November 19, 2015 3:28 PM EST

Oppenheimer analyst Christopher Marai said they would be buyers of Sarepta Therapeutic (NASDAQ: SRPT) into Kyndrisa briefing documents and panel outcome. The firm reiterated an Outperform rating and price target of $45.

"Tomorrow morning, the FDA will make available briefing documents (here) pertaining to the... More

Sarepta Therapeutics (SRPT) Issues Publication of Positive Eteplirsen Phase 2b Long-Term Data in DMD

November 17, 2015 8:44 AM EST

Sarepta Therapeutics (Nasdaq: SRPT) announced that the Annals of Neurology published online [link to final article] positive efficacy and safety results from a Phase IIb long-term open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The study found that at three years of treatment, patients experienced a slower rate of disease progression when compared to untreated matched historical controls and the investigational drug continued to be well-tolerated.

This analysis used historical data from the Italian Telethon Network and the Leuven Neuromuscular Reference Group for comparative... More